Study details
Enrolling now
Continued Access to and Assessment of Long-Term Safety
Daiichi Sankyo
NCT IDNCT06174987ClinicalTrials.gov data as of Apr 2026
Phase
Phase 3
Target enrollment
50
Study length
about 4 years
Ages
18+
Locations
2 sites in FL, NC
About this study
This trial is testing a treatment called T-DXd in people with advanced or metastatic cancer. The goal is to see if this treatment is safe for long-term use.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take T-DXd
PhasePhase 3
Primary goalNumber of Participants Reporting Treatment-emergent Adverse Events Leading to Study Drug discontinuation and/or Dose Reduction, Treatment-emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (AESIs)
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low5%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Number of Participants Reporting Treatment-emergent Adverse Events Leading to Study Drug discontinuation and/or Dose Reduction, Treatment-emergent Serious Adverse Events (TESAEs), and Treatment-emergent Adverse Events of Special Interest (AESIs)